Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma

Bone Marrow Transplantation

Volumn 19, Issue 2, 1997, Pages 121-127

  De Lima, M ^a   Van Besien, K W ^a   Giralt, S A ^a   Khouri, I F ^a   Mehra, R ^a   Andersson, B S ^a   Przepiorka, D ^a   Gajewski, J L ^a   Korbling, M ^a   Champlin, R E ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

BMT; Lymphoma; Relapse

Indexed keywords

BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; MELPHALAN; METHYLPREDNISOLONE; THIOTEPA;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW TRANSPLANTATION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; WHOLE BODY RADIATION;

EID: 0031014428     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700614     Document Type: Article

References (24)

1. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relaspes of chemotherapy-sensitive non-Hodgkin's lymphoma. New Engl J Med 1995; 333: 1540-1545.
2. Gianni AM, Bregni M, Siena S et al. 5-Year update of the Milan cancer institute randomized trial of high-dose sequential vs MACOP-B therapy for diffuse large cell lymphoma. ASCO Proc 1994; 13: 373.
3. Haioun C, Lepage E, Gisselbrecht C et al. Comparison of autologous bone marrow transplantation with sequential chemotherapy for inetmediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 Patients. J Clin Oncol 1994; 12: 2543-2551.
4. Vose JM, Bierman PJ, Anderson JR et al. Progressive disease after high-dose chemotherapy and autologous marrow transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood 1992; 80: 2142-2148.
5. Goldstein NI, Nagle R, Villar H et al. Isolation and characterization of a human monoclonal antibody which reacts with breast and colorectal carcinoma. Anticancer Res 1990; 10: 1491-1500.
6. Appelbaum FR. Treatment of aggressive non-Hodgkin's lymphoma with marrow transplantation. Marrow Transplant Rev 1993; 3: 1-16.
7. Scheuten HC, Armitage JO, Klassen LW et al. Allogeneic bone marrow transplantation in patients with lymphoma relapsing after autologous transplantation. Bone Marrow Transplant 1989; 4: 119-121.
8. van Besien K, Mehra R, Giralt SA et al. Allogeneic bone marrow transplantation for poor prognosis lymphoma. Response, toxicity and survival depend on disease histology. Am J Med 1996; 100: 299-307.
9. Giralt SA, LeMaistre CF, Vriesendorp HM et al. Etoposide, cyclophosphamide, total-body irradiation, and allogeneic bone marrow transplantation for hematologic malignancies. J Clin Ontol 1994; 12: 1923-1930.
10. Van Besien KW, Tabocoff J, Rodriguez MA et al. Intensive chemotherapy with the BEAC regimen and autologous bone marrow transplantation in patients with refractory or recurrent intermediate grade and immunoblastic lymphoma; toxicity, long-term follow-up and identification of prognostic factors. Bone Marrow Transplant 1995; 15: 549-555.
11. Przepiorka D, Ippoliti C, Giralt S et al. A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic bone marrow transplantation. Bone Marrow Transplant 1994; 14: 449-453.
12. Przepiorka D, Nath R, Ippoliti C et al. A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for autologous transplantation for malignant lymphoma. Leuk Lymphoma 1995; 17: 427-433.
13. Van Besien KW, Demuynck H, LeMaistre CF et al. High dose melphalan allows durable engraftment of allogeneic bone marrow. Bone Marrow Transplant 1995; 15: 321-323.
14. Van Besien KW, Khouri IF, Giralt SA et al. Allogeneic bone marrow transplantation for refractory and recurrent low grade lymphoma - the case for aggressive management. J Clin Oncol 1995; 13: 1096-1102.
15. Korbling M, Przepiorka D, Huh YO et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995; 85: 1659-1665.
16. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1568.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
18. Frei E III, Holden SA, Gonin R et al. Antitumor alkylating agents: in vitro cross-resistance and collateral sensitivity studies. Cancer Chemother Pharmacol 1993; 33: 113-122.
19. Ratanatharathorn V, Uberti J, Karanes C et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood 1994; 84: 1050-1055.
20. Jones RJ, Ambinder RF, Piantadosi S, Santos GW. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991; 77: 649-653.
21. Tricot G, Jagannath S, Vesole D et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588-596.
22. Tsai T, Goodman S, Schiller G et al. Allogeneic bone marrow transplantation for relapse after autologous bone marrow transplantation in lymphomas and acute leukemia. Blood 1995; 86: 969a (Abstr.).
23. Vandenberghe E, Pearce R, Taghipour G, Goldstone AH. Two autotransplants for lymphoma - acceptable toxicity (18%) of the second transplant and significant survival length in some patients. Data from the EBMT lymphoma registry. Blood 1995; 86: 971A (Abstr.).
24. Barrett AJ, Locatelli F, Treleaven JG et al. Second transplants for leukaemic relapse after bone marrow transplantation: high early mortality but favourable effect of chronic GVHD on continued remission. A report by the EBMT Leukaemia working party. Br J Haematol 1991; 79: 567-574.